Status:
COMPLETED
Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Acute Renal Failure
Eligibility:
All Genders
18+ years
Brief Summary
1. Sustained low efficiency daily hemodiafiltration(SLEDD-f) is a kind of renal replacement therapy with high-flux dialyser membrane (helixone). 2. The pore size of helixone is larger than most antibi...
Detailed Description
Vancomycin is the most important antibiotic in the treatment of resistant G(+) bacteria infections. Close monitor of serum level is important to ensure its safety and effectiveness. So far there is no...
Eligibility Criteria
Inclusion
- Acute renal failure of any cause
- Use SLEDD-f as renal replacement therapy
- Priscribe vancomycin for a known or suspected infection
Exclusion
- None
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00780351
Start Date
October 1 2008
End Date
August 1 2009
Last Update
October 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan